17/06/2024, 18:34 Inocras, IMBdx Partner on Cancer Diagnostics in US | 360Dx

Inocras, IMBdx Partner on Cancer Diagnostics in US

May 22, 2024 | staff reporter

Save for later

NEW YORK – Inocras and IMBdx said Wednesday that they have signed a partnership to bring
IMBdx's liquid biopsy tests to the US.

Financial and other details of the deal were not disclosed.

"Our collaboration with IMBdx marks a significant step forward in our mission to transform
healthcare for cancer and rare disease patients," Inocras CEO Jehee Suh said in a statement. "By
combining our strengths, we're not just delivering advanced diagnostic services, we're contributing
to creating a pathway to a more effective cancer care journey."

Inocras, formerly known as Genome Insight, is a spinout from the Korea Advanced Institute of
Science and Technology specializing in whole-genome sequencing for cancer profiling. In 2022, the
firm moved its headquarters to San Diego. It has launched two diagnostic whole-genome
sequencing tests: CancerVision for solid tumors and RareVision for rare diseases.

Last year, South Korea-based IMBdx expanded its partnership with AstraZeneca focused on liquid
biopsy for prostate cancer.

Filed Under Business News Liquid Biopsy Clinical Sequencing

Molecular Diagnostics Cancer North America Asia/Oceania

distribution agreement sequencing-based diagnostics

Privacy Policy. Terms & Conditions. Copyright © 2024 GenomeWeb, a business unit of Crain
Communications. All Rights Reserved.

https://www.360dx.com/business-news/inocras-imbdx-partner-cancer-diagnostics-us 1/1